Silence Therapeutics(SLN)
$19.81-0.01 (-0.05%)
SLN
Silence Therapeutics financials statements
$19.81
At close:-0.01 (-0.05%)
Want to see SLN full AI Analyst Report?
Silence Therapeutics (SLN) Ratios
395 Followers
Silence Therapeutics Ratios
SLN's free cash flow for Q3 2026 was £-12.75M. For the 2026 fiscal year, SLN's free cash flow was decreased by £-3.00 and operating cash flow was £-12.75M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 8.72 | 11.14 | 4.62 | 4.41 | 5.69 |
| Quick Ratio | 8.72 | 11.14 | 4.62 | 4.41 | 5.69 |
| Cash Ratio | 0.83 | 7.21 | 3.08 | 2.50 | 4.85 |
| Solvency Ratio | -1.27 | -0.82 | -0.44 | -0.58 | -0.44 |
| Operating Cash Flow Ratio | -4.57 | -4.02 | -1.76 | -2.60 | 0.61 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -172.59 | 0.00 | 0.00 |
| Net Current Asset Value | ÂŁ 49.52M | ÂŁ 94.90M | ÂŁ 5.70M | ÂŁ 11.26M | ÂŁ -1.33M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.02 | 0.02 | 0.02 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.02 | 0.02 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.11 | 1.51 | 5.43 | 4.87 | 11.28 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | -163.11 | -1300.68 | -4871.88 |
| Interest Coverage Ratio | 0.00 | 0.00 | -1458.94 | -1298.72 | -5726.75 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.03 | 0.05 | 0.00 |
| Net Debt to EBITDA | 0.13 | 1.98 | 1.37 | 0.90 | 1.62 |
| Profitability Margins | |||||
| Gross Profit Margin | 61.54% | 72.70% | 59.34% | 37.83% | 39.94% |
| EBIT Margin | -15849.91% | -114.62% | -198.13% | -281.87% | -369.30% |
| EBITDA Margin | -15750.63% | -113.25% | -196.17% | -279.12% | -365.86% |
| Operating Profit Margin | -16055.99% | -146.38% | -195.48% | -281.87% | -369.02% |
| Pretax Profit Margin | -15849.91% | -102.79% | -198.27% | -229.26% | -369.36% |
| Net Profit Margin | -15851.88% | -104.74% | -170.51% | -232.44% | -317.44% |
| Continuous Operations Profit Margin | -15851.88% | -104.74% | -170.51% | -232.44% | -317.44% |
| Net Income Per EBT | 100.01% | 101.90% | 86.00% | 101.39% | 85.94% |
| EBT Per EBIT | 98.72% | 70.22% | 101.42% | 81.33% | 100.09% |
| Return on Assets (ROA) | -67.42% | -27.98% | -36.22% | -46.82% | -40.97% |
| Return on Equity (ROE) | -142.23% | -42.31% | -196.73% | -228.04% | -462.23% |
| Return on Capital Employed (ROCE) | -76.17% | -42.64% | -51.08% | -71.34% | -56.54% |
| Return on Invested Capital (ROIC) | -76.11% | -42.62% | -43.83% | -70.97% | -48.51% |
| Return on Tangible Assets | -73.52% | -29.39% | -39.66% | -50.75% | -44.49% |
| Earnings Yield | -92.57% | -53.46% | -25.62% | -37.20% | -7.53% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.02 | 2.01 | 1.06 | 23.67 | 37.51 |
| Payables Turnover | 0.05 | 4.00 | 3.08 | 4.23 | 1.83 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.32 | 27.41 | 10.99 | 9.84 | 6.39 |
| Asset Turnover | 0.00 | 0.27 | 0.21 | 0.20 | 0.13 |
| Working Capital Turnover Ratio | 0.00 | 0.40 | 0.33 | 0.30 | 0.20 |
| Cash Conversion Cycle | 8586.71 | 90.12 | 226.46 | -70.95 | -189.27 |
| Days of Sales Outstanding | 16071.75 | 181.43 | 344.89 | 15.42 | 9.73 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 7485.05 | 91.30 | 118.44 | 86.38 | 199.00 |
| Operating Cycle | 16071.75 | 181.43 | 344.89 | 15.42 | 9.73 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.96 | -3.51 | -3.18 | -5.32 | 0.31 |
| Free Cash Flow Per Share | -3.96 | -3.52 | -3.19 | -5.37 | 0.25 |
| Dividend Paid and CapEx Coverage Ratio | -1132.20 | -320.57 | -874.44 | -104.67 | 5.10 |
| Capital Expenditure Coverage Ratio | -1132.20 | -320.57 | -874.44 | -104.67 | 5.10 |
| Operating Cash Flow Coverage Ratio | -389.19 | -578.12 | -113.73 | -127.90 | 67.05 |
| Operating Cash Flow to Sales Ratio | -111.40 | -1.25 | -1.55 | -2.63 | 0.74 |
| Free Cash Flow Yield | -65.11% | -63.97% | -23.33% | -42.57% | 1.41% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.07 | -2.32 | -3.90 | -2.69 | -13.28 |
| Price-to-Sales (P/S) Ratio | 171.24 | 1.96 | 6.65 | 6.25 | 42.15 |
| Price-to-Book (P/B) Ratio | 1.54 | 0.79 | 7.68 | 6.13 | 61.38 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.54 | -1.56 | -4.29 | -2.35 | 70.86 |
| Price-to-Operating Cash Flow Ratio | -1.54 | -1.57 | -4.29 | -2.37 | 56.98 |
| Price-to-Earnings Growth (PEG) Ratio | -0.01 | 0.07 | 0.45 | -0.01 | -0.65 |
| Enterprise Value Multiple | -0.96 | 0.25 | -2.02 | -1.34 | -9.91 |
| Enterprise Value | 84.61M | -12.10M | 100.43M | 80.92M | 449.95M |
| EV to EBITDA | -0.96 | 0.25 | -2.02 | -1.34 | -9.91 |
| EV to Sales | 151.35 | -0.28 | 3.96 | 3.74 | 36.24 |
| EV to Free Cash Flow | -1.36 | 0.22 | -2.55 | -1.41 | 60.93 |
| EV to Operating Cash Flow | -1.36 | 0.22 | -2.55 | -1.42 | 48.98 |
| Tangible Book Value Per Share | 3.26 | 6.44 | 0.94 | 1.28 | 0.03 |
| Shareholders’ Equity Per Share | 3.96 | 6.95 | 1.78 | 2.06 | 0.29 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.02 | 0.14 | -0.01 | 0.14 |
| Revenue Per Share | 0.04 | 2.81 | 2.05 | 2.02 | 0.42 |
| Net Income Per Share | -5.63 | -2.94 | -3.50 | -4.69 | -1.33 |
| Tax Burden | 1.00 | 1.02 | 0.86 | 1.01 | 0.86 |
| Interest Burden | 1.00 | 0.90 | 1.00 | 0.81 | 1.00 |
| Research & Development to Revenue | 121.20 | 1.57 | 1.73 | 2.01 | 2.48 |
| SG&A to Revenue | 39.97 | 0.62 | 0.81 | 1.19 | 1.61 |
| Stock-Based Compensation to Revenue | 14.44 | 0.24 | 0.51 | 0.59 | 0.94 |
| Income Quality | 0.70 | 1.87 | 0.78 | 1.13 | -0.15 |
Currency in GBP

